Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2024-10-17 DOI:10.1016/j.jhep.2024.10.010

Guanglin Xiao, Hong Ren

引用次数: 0

Abstract

Section snippets

Financial support

This work was supported by a Remarkable Innovation-Clinical Research Project and the DengFeng Program of the Second Affiliated Hospital of Chongqing Medical University

Authors’ contributions

G.X.: Manuscript writing & Study design. H.R.: Manuscript revision & Study design.

Declaration of Competing Interest

The authors do not have any disclosures to report.Please refer to the accompanying ICMJE disclosure form for further details.

查看原文本刊更多论文

肝细胞癌患者是乙型肝炎免疫检查点抑制剂的理想研究人群

本研究得到重庆医科大学附属第二医院 "重大创新-临床研究 "项目和 "登峰计划 "的支持：手稿撰写& 研究设计。H.R.: 手稿修改 & 研究设计。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.